HK1–LDHA feedback boosts Wnt5a histone lactylation, linking prenatal acetaminophen to male OA

A new study is drawing attention to how prenatal drug exposure can shape disease risk long after birth, pointing to an unexpected epigenetic pathway involving lactylation and Wnt signaling. Researchers report that an HK1–LDHA feedback loop helps drive histone lactylation at the Wnt5a locus, effectively tuning gene expression during developmental windows.

The work centers on metabolic enzymes that are often discussed in cancer biology but increasingly recognized as regulators of chromatin. HK1 (hexokinase 1) and LDHA (lactate dehydrogenase A) together influence intracellular lactate availability, which in turn supports histone lactylation—a chemical modification linked to transcriptional activation.

Using mechanistic experiments, the authors show that the HK1–LDHA axis can create a self-reinforcing cycle. This feedback regulation amplifies lactate production, promoting lactylation of histones near Wnt5a and altering how strongly the gene is expressed. Because Wnt pathways govern differentiation, inflammation, and tissue maintenance, these changes may establish long-term molecular “settings” relevant to musculoskeletal health.

The study also connects these molecular events to a real-world exposure scenario: prenatal acetaminophen. In male offspring, acetaminophen exposure during gestation was associated with increased susceptibility to osteoarthritis, suggesting that fetal timing and sex-specific biology may influence epigenetic outcomes.

Importantly, the researchers link the osteoarthritis phenotype to the lactylation machinery rather than treating it as a purely downstream consequence. Their findings indicate that histone lactylation at Wnt5a acts as a mediator between prenatal acetaminophen and later disease vulnerability.

Although osteoarthritis is frequently viewed through the lens of biomechanics and aging, this research emphasizes that early metabolic-epigenetic reprogramming can prime joint tissues for later degeneration. That shift could influence how clinicians think about risk stratification after pregnancy exposures.

The results raise new questions about whether targeting lactate metabolism or lactylation-related regulators could blunt susceptibility. They also suggest broader implications for other prenatal stressors that alter cellular metabolism during development.

For now, the study offers a viral-science-news-ready message: a drug given during pregnancy may change a fetus’s chromatin chemistry via lactate-driven histone lactylation, ultimately reshaping Wnt5a-driven biology and affecting future osteoarthritis risk in males.